帕金森病新药Opicapone的研究进展

Abstract
Figure/Table
References (32)
Related Citation (15)

Download: PDF (776 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Parkinson′s disease (PD) is the second most common neurodegenerative disease after Alzheimer′s disease. At present, the main way to treat PD is still Levodopa therapy. However, long-term use of Levodopa can lead to a series of side effects, such as dyskinesia, decreased efficacy, "on-off" phenomena, end of dose phenomena, and soon. The catechol-O-methyltransferase (COMT) inhibitor can inhibit the metabolism of surrounding Levodopa and increase the transmission amount of Levodopa, so it is used in Levodopa additional therapy to enhance the efficacy of Levodopa. As a new third-generation COMT inhibitor, Opicapone can be used in Levodopa addition therapy to improve the motor fluctuations and end of dose phenomena. Opicapone has sustained activity in vivo for a long time. The current recommended dose is 50 mg per day taken orally before bedtime. The half-life of opicapone-induced COMT inhibitors is longer than that of the previous two generations of Opicapone inhibitors, and can significantly increase Levodopa systemic exposure, with more effective, safer and more lasting properties.

Key words： Parkinson′s disease Opicapone Levodopa Catechol-O-methyltransferase inhibitor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Xinjie1 LUO Enli2 CHEN Yafang1 LUO Xiaodong2 ZHENG Chunye2

Cite this article:

CHEN Xinjie1 LUO Enli2 CHEN Yafang1 LUO Xiaodong2 ZHENG Chunye2. Research progress of new drug Opicapone for Parkinson′s disease[J]. 中国医药导报, 2019, 16(20): 29-33.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I20/29

[1] 刘疏影，陈彪.帕金森病流行现状[J].中国现代神经疾病杂志，2016，16（2）：98-101.
[2] Lang AE，Lozano AM. Parkinson′s disease [J]. N Engl J Med，1998，339（16）：1130-1143.
[3] Kaakkola S，Gordin A，M?覿nnist?觟 PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase [J]. Gen Pharmacol，1994，25（5）：813-824.
[4] Bonifácio MJ，Palma PN，Almeida L，et al. Catechol-O-methyltransferase and its inhibitors in Parkinson′s disease [J]. Drugs，2007，13（3）：352-379.
[5] European Medicines Agency. Ongentys 25 mg hard capsules：summary of product characteristics [EB/OL]. 2016. http：//www.ema.europa.eu.
[6] LeWitt PA. Levodopa for the treatment of Parkinson's disease [J]. N Engl J Med，2008，359（23）：2468-2476.
[7] Hauser RA. Levodopa：past，present，and future [J]. Eur Neurol，2009，62（1）：1-8.
[8] Gomes P，Soares-da-Silva P. Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells [J]. Neuropharmacology，1999，38（9）：1371-1380.
[9] Kiss LE，Ferreira HS，Torrao L，et al. Discovery of a long-acting，peripherally selective inhibitor of catechol-O-methyltransferase [J]. J Med Chem，2010，53（8）：3396-3411.
[10] Bonif?觃cio MJ，Torr?觔o L，Loureiro AI，et al. Pharmacological profile of opicapone，a third-generation nitrocatechol catechol-O-methyl transferase inhibitor，in the rat [J]. Br J Pharmacol，2015，172（7）：1739-1752.
[11] Bonifácio MJ，Torr?觔o L，Loureiro AI，et al. 2.243 OPICAPONE：CHARACTERIZATION OF A NOVEL PERIPHERAL LONG-ACTING CATECHOL-O-METHYLTRANSFERASE INHIBITOR [J]. Parkinsonism Relat Disord，2012，18（Suppl 2）：S125.
[12] Deane K，Spieker S，Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson′s disease [J]. Cochrane Database Syst Rev，2004（4）：CD004554.
[13] Ceravolo R，Piccini P，Bailey DL，et al. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease [J]. Synapse，2002，43（3）：201-207.
[14] Scott LJ. Opicapone in Parkinson′s disease：a profile of its use [J]. Drugs，2017，33（7）：303-310.
[15] Bonifácio MJ，Sutcliffe JS，Torr?觔o L，et al. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone，a third generation nitrocatechol COMT inhibitor [J]. Neuron，2014，77：334-341.
[16] Almeida L，Rocha JF，Falc?觔o A，et al. Pharmacokinetics，Pharmacodynamics and Tolerability of Opicapone，a Novel Catechol-O-Methyltransferase Inhibitor，in Healthy Subjects [J]. Clin Pharmacokinet，2013，52（2）：139-151.
[17] Falc?觔o A，Rocha JF，Santos A，et al. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects [J]. Clin Pharmacol Drug Dev，2016，5（2）：150-161.
[18] Rocha JF，Ferreira JJ，Falc?觔o A，et al. Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics，catechol-O-methyltransferase activity and motor response in patients with Parkinson disease [J]. Clin Pharmacol Drug De，2016，5（3）：232-240.
[19] Rocha JF，Almeida L，Falc?觔o A，et al. Opicapone：a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects [J]. Br J Clin Pharmacol，2013，76（5）：763-775.
[20] Rocha JF，Santos A，Falc?觔o A，et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone [J]. Eur J Clin Pharmacol，2014，70（3）：279-286.
[21] Scott LJ. Opicapone：a review in Parkinson′s disease [J]. Drugs，2016，76（13）：1293-1300.
[22] Ferreira JJ，Lees A，Rocha JF，et al. Opicapone as an adjunct to levodopa in patients with Parkinson′s disease and end-of-dose motor fluctuations：a randomised，double-blind，controlled trial [J]. Lancet Neurol，2016，15（2）：154-165.
[23] Lees A，Ferreira J，Costa R，et al. Efficacy and safety of opicapone，a new COMT inhibitor，for the treatment of motor fluctuations in Parkinson′s Disease patients：a phase Ⅲ，randomized，double-blind，placebo-controlled，parallel-group study（BIPARK Ⅱ）[J]. Mov Disord，2013，333：e116.
[24] Costa R，Oliveira C，Pinto R，et al. One-year open-label efficacy and safety of opicapone in Parkinson′s disease BIPARK-Ⅱ study [J]. Mov Disord，2014，29（Suppl 1）：S233.
[25] Lees A，Ferreira J，Lopes N，et al. Efficacy and safety of opicapone in patients over 70 years with Parkinson′s disease and motor fluctuations [J]. Mov Disord，2015，30：S99.
[26] Pinto R，Hostis P，Patat A，et al. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study [J]. Clin Pharmacol Drug Dev，2015，4（6）：454-462.
[27] Ferreira J，Lees A，Gama H，et al. Safety and tolerability of opicapone in the treatment of Parkinson′s disease and motor fluctuations：analysis of pooled phase Ⅲ studies [J]. Mov Disord，2015，30（Suppl 1）：S86.
[28] Scaglione F. New oral anticoagulants：comparative pharmacology with vitamin K antagonists [J]. Clin Pharmacokinet，2013，52（2）：69-82.
[29] Vaz-Da-Silva M，Pinto R，Lopes N，et al. Evaluation of opicapone′s cardiac safety in patients with Parkinson′s disease：analysis of the centralized phase Ⅲ ECG dataset [J]. Eur J Neurol，2015，22：818.
[30] Lees AJ，Ferreira J，Rascol O，et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations：a randomized clinical trial [J]. JAMA Neuro，2017，74（2）：197-206.
[31] Ferreira JJ，Rocha JF，Falc?觔o A，et al. Effect of opicapone on levodopa pharmacokinetics，catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson′s disease [J]. Eur J Neurol，2015，22（5）：815-825，e56.
[32] Goetz CG，Tilley BC，Shaftman SR，et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale（MDS-UPDRS）：scale presentation and clinimetric testing results [J]. Mov Disord，2008，23（15）：2129-2170.